Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats

Craig D. Fisher, Andrew J. Lickteig, Lisa M. Augustine, Ronald P J Oude Elferink, David G. Besselsen, Robert P. Erickson, Nathan J Cherrington

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of diagnoses ranging from simple fatty liver (SFL), to non-alcoholic steatohepatitis (NASH). This study aimed to determine the effect of moderate and severe NAFLD on hepatic transporter expression and function in vivo. Rats were fed a high-fat diet (SFL model) or a methionine-choline-deficient diet (NASH model) for eight weeks. Hepatic uptake transporter function was determined by bromosulfophthalein (BSP) disposition. Transporter expression was determined by branched DNA signal amplification assay and western blotting; inflammation was identified by immunostaining of liver slices for interleukin 1 beta (IL-1β). MC- rats showed significant retention of BSP in the plasma when compared to control rats. Hepatic NTCP, OATP1a1, 1a4, 1b2 and 2b1; and OAT 2 and 3 mRNA levels were significantly decreased in high-fat and MC- diet rats when compared to control. Protein expression of OATP1a1 was significantly decreased in high-fat animals, while OATP1a1 and OATP1b2 expressions were significantly lower in MC- rats when compared to control. Liver tissue from high-fat and MC- rats stained positive for IL-1β, a pro-inflammatory cytokine known to decrease expression of NTCP, OATP and OAT transporters, suggesting a plausible mechanism for the observed transporter alterations. These data suggest that different stages of NAFLD result in altered hepatic uptake transporter expression that can lead to a functional impairment of xenobiotic uptake from the blood. Furthermore, NAFLD may alter the plasma retention time of clinically relevant drugs that are reliant on these transporters and may increase the potential drug toxicity.

Original languageEnglish (US)
Pages (from-to)119-127
Number of pages9
JournalEuropean Journal of Pharmacology
Volume613
Issue number1-3
DOIs
StatePublished - Jun 24 2009

Fingerprint

Fatty Liver
Liver
Sulfobromophthalein
High Fat Diet
Interleukin-1beta
Branched DNA Signal Amplification Assay
Fats
Organic Anion Transporters
Xenobiotics
Choline
Drug-Related Side Effects and Adverse Reactions
Methionine
Non-alcoholic Fatty Liver Disease
Western Blotting
Cytokines
Diet
Inflammation
Messenger RNA
Pharmaceutical Preparations
Proteins

Keywords

  • Fatty liver disease
  • Hepatic uptake transport
  • Inflammation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. / Fisher, Craig D.; Lickteig, Andrew J.; Augustine, Lisa M.; Oude Elferink, Ronald P J; Besselsen, David G.; Erickson, Robert P.; Cherrington, Nathan J.

In: European Journal of Pharmacology, Vol. 613, No. 1-3, 24.06.2009, p. 119-127.

Research output: Contribution to journalArticle

Fisher, Craig D. ; Lickteig, Andrew J. ; Augustine, Lisa M. ; Oude Elferink, Ronald P J ; Besselsen, David G. ; Erickson, Robert P. ; Cherrington, Nathan J. / Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. In: European Journal of Pharmacology. 2009 ; Vol. 613, No. 1-3. pp. 119-127.
@article{083e983fc5d341af8a414dff1a6eb4a9,
title = "Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats",
abstract = "Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of diagnoses ranging from simple fatty liver (SFL), to non-alcoholic steatohepatitis (NASH). This study aimed to determine the effect of moderate and severe NAFLD on hepatic transporter expression and function in vivo. Rats were fed a high-fat diet (SFL model) or a methionine-choline-deficient diet (NASH model) for eight weeks. Hepatic uptake transporter function was determined by bromosulfophthalein (BSP) disposition. Transporter expression was determined by branched DNA signal amplification assay and western blotting; inflammation was identified by immunostaining of liver slices for interleukin 1 beta (IL-1β). MC- rats showed significant retention of BSP in the plasma when compared to control rats. Hepatic NTCP, OATP1a1, 1a4, 1b2 and 2b1; and OAT 2 and 3 mRNA levels were significantly decreased in high-fat and MC- diet rats when compared to control. Protein expression of OATP1a1 was significantly decreased in high-fat animals, while OATP1a1 and OATP1b2 expressions were significantly lower in MC- rats when compared to control. Liver tissue from high-fat and MC- rats stained positive for IL-1β, a pro-inflammatory cytokine known to decrease expression of NTCP, OATP and OAT transporters, suggesting a plausible mechanism for the observed transporter alterations. These data suggest that different stages of NAFLD result in altered hepatic uptake transporter expression that can lead to a functional impairment of xenobiotic uptake from the blood. Furthermore, NAFLD may alter the plasma retention time of clinically relevant drugs that are reliant on these transporters and may increase the potential drug toxicity.",
keywords = "Fatty liver disease, Hepatic uptake transport, Inflammation",
author = "Fisher, {Craig D.} and Lickteig, {Andrew J.} and Augustine, {Lisa M.} and {Oude Elferink}, {Ronald P J} and Besselsen, {David G.} and Erickson, {Robert P.} and Cherrington, {Nathan J}",
year = "2009",
month = "6",
day = "24",
doi = "10.1016/j.ejphar.2009.04.002",
language = "English (US)",
volume = "613",
pages = "119--127",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats

AU - Fisher, Craig D.

AU - Lickteig, Andrew J.

AU - Augustine, Lisa M.

AU - Oude Elferink, Ronald P J

AU - Besselsen, David G.

AU - Erickson, Robert P.

AU - Cherrington, Nathan J

PY - 2009/6/24

Y1 - 2009/6/24

N2 - Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of diagnoses ranging from simple fatty liver (SFL), to non-alcoholic steatohepatitis (NASH). This study aimed to determine the effect of moderate and severe NAFLD on hepatic transporter expression and function in vivo. Rats were fed a high-fat diet (SFL model) or a methionine-choline-deficient diet (NASH model) for eight weeks. Hepatic uptake transporter function was determined by bromosulfophthalein (BSP) disposition. Transporter expression was determined by branched DNA signal amplification assay and western blotting; inflammation was identified by immunostaining of liver slices for interleukin 1 beta (IL-1β). MC- rats showed significant retention of BSP in the plasma when compared to control rats. Hepatic NTCP, OATP1a1, 1a4, 1b2 and 2b1; and OAT 2 and 3 mRNA levels were significantly decreased in high-fat and MC- diet rats when compared to control. Protein expression of OATP1a1 was significantly decreased in high-fat animals, while OATP1a1 and OATP1b2 expressions were significantly lower in MC- rats when compared to control. Liver tissue from high-fat and MC- rats stained positive for IL-1β, a pro-inflammatory cytokine known to decrease expression of NTCP, OATP and OAT transporters, suggesting a plausible mechanism for the observed transporter alterations. These data suggest that different stages of NAFLD result in altered hepatic uptake transporter expression that can lead to a functional impairment of xenobiotic uptake from the blood. Furthermore, NAFLD may alter the plasma retention time of clinically relevant drugs that are reliant on these transporters and may increase the potential drug toxicity.

AB - Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of diagnoses ranging from simple fatty liver (SFL), to non-alcoholic steatohepatitis (NASH). This study aimed to determine the effect of moderate and severe NAFLD on hepatic transporter expression and function in vivo. Rats were fed a high-fat diet (SFL model) or a methionine-choline-deficient diet (NASH model) for eight weeks. Hepatic uptake transporter function was determined by bromosulfophthalein (BSP) disposition. Transporter expression was determined by branched DNA signal amplification assay and western blotting; inflammation was identified by immunostaining of liver slices for interleukin 1 beta (IL-1β). MC- rats showed significant retention of BSP in the plasma when compared to control rats. Hepatic NTCP, OATP1a1, 1a4, 1b2 and 2b1; and OAT 2 and 3 mRNA levels were significantly decreased in high-fat and MC- diet rats when compared to control. Protein expression of OATP1a1 was significantly decreased in high-fat animals, while OATP1a1 and OATP1b2 expressions were significantly lower in MC- rats when compared to control. Liver tissue from high-fat and MC- rats stained positive for IL-1β, a pro-inflammatory cytokine known to decrease expression of NTCP, OATP and OAT transporters, suggesting a plausible mechanism for the observed transporter alterations. These data suggest that different stages of NAFLD result in altered hepatic uptake transporter expression that can lead to a functional impairment of xenobiotic uptake from the blood. Furthermore, NAFLD may alter the plasma retention time of clinically relevant drugs that are reliant on these transporters and may increase the potential drug toxicity.

KW - Fatty liver disease

KW - Hepatic uptake transport

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=65749086891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749086891&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2009.04.002

DO - 10.1016/j.ejphar.2009.04.002

M3 - Article

C2 - 19358839

AN - SCOPUS:65749086891

VL - 613

SP - 119

EP - 127

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -